Agenda & Faculty, May 3-4, 2024
Lymphoma Day
08:00am
Industry supported independent expert discussion Supported by Abbvie
09:00am
Coffee Break
09:30am
Opening remarks – Ryan Fitzpatrick, CEO, MD Education
Session I
Moderators: Susan O’Brien, MD, University of California
09:35am
Clonal Heterogeneity in CLL and opportunities for immune targeting.
Catherine Wu, MD - Dana-Farber Cancer Institute, Massachusetts
09:55am
How I choose which frontline treatment I use in which patient
Matthew Davids, MD - Dana-Farber Cancer Institute, Massachusetts
10:15am
Interesting/Unusual Cases in CLL
Alessandra Ferrajoli, MD - MD Anderson Cancer Center, Houston, Texas
10:35am
Panel Discussion
11:55am
Coffee Break
Session II
Moderators: Sameer Parikh, MD, Mayo Clinic
11:15am
Small molecule combinations
John Allan, MD - Weill Cornell Medicine, New York
11:35am
MRD in CLL, is it ready for use in practice?
Neil Kay, MD - Mayo Clinic, Minnesota
Debate: BTKi or Ven G for non-17p deleted patients with Unmutated IGHV
11:55pm
BTKi
Nicole Lamanna, MD - Herbert Irving Comprehensive Cancer Center, New York
12:15pm
VenG
Mazyar Shadman, MD - Fred Hutchinson Cancer Center, Washington
12:35pm
Panel Discussion
12:55pm
Lunch Break + Group Photo
13:45pm
Industry supported independent expert discussion supported by Lilly
Session III
Moderators: Catherine Coombs, MD, UCI Health
14:30pm
CART in CLL
David Maloney, MD - Fred Hutchinson Cancer Center, Washington
14:50pm
Non-covalent BTKi
Catherine Coombs, MD - UCI Health, California
15:10pm
Richters syndrome, what’s on the horizon
Adam Kittai, MD - Mount Sinai School of Medicine
15:35pm
Panel Discussion
15:50pm
Coffee Break
Session IV
Moderators: Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
Debate: MRD + at 1 year of VenG: Stop Therapy or continue
16:10pm
Pro stopping
Danielle Brander, MD Duke University, North Carolina
16:30pm
Con stopping
Alexey Danilov, MD City of Hope, California
16:50pm
Monoclonal B cell lymphocytosis – what’s new in 2024?
Sameer Parikh, MD - Mayo Clinic, Minnesota
17:10pm
CLL, Next Questions
Rick Furman, MD - Weill Cornell Medicine, New York
17:30pm
Panel Discussion
17:50pm
Adjourn
Lymphoma Day
08:00am
Industry supported independent expert discussion Pharmacyclics an AbbVie Company
08:45am
Coffee Break
Session V: New Approaches for First-line therapy in B-cell Lymphoma
Moderators: Roni Shouval, MD, PhD Memorial Sloan Kettering Cancer Center, Mark Roschewski, MD, National Cancer Institute
09:00am
Novel Strategies for first-line treatment of DLBCL
Christopher Flowers, MD - MD Anderson Cancer Center, Houston, Texas
09:20am
Strategies for identifying and addressing poor-risk, follicular lymphoma in the first-line
Paolo Strati, MD - MD Anderson Cancer Center, Houston, Texas
09:40am
What’s now and what’s next for first-line therapy in MCL
John P. Leonard, MD - Weill Cornell Medicine, New York
10:00am
Panel Discussion
10:20am
Coffee Break
Session VI: New developments in the application of cfDNA: Future Directions and Future Leaders
Moderators: Elise Chong, MD, University of Pennsylvania, Paolo Strati, MD, MD Anderson Cancer Center
10:40am
Cell-free DNA assessment
Mark Roschewski, MD - National Cancer Institute, Nebraska
11:00am
Optimizing ctDNA limits of detection for DLBCL during first line therapy
Jordan Scott Goldstein, MD - Stanford Medicine, Palo Alto, California
11:20am
Application of cfDNA technologies in FL
Paolo Strati, MD - MD Anderson Cancer Center, Houston, Texas
Debate: Bringing Molecular Testing to First-line therapy in DLBCL
11:40am
Test-the Test - Can we do molecular testing in the real world?
Dai Chihara, MD - MD Anderson Cancer Center, Houston, Texas
12:00pm
Bringing DuoSeq to Practice
Sandeep Dave, MD - Duke University School of Medicine, North Carolina
12:20pm
Panel Discussion
12:40pm
Lunch Break
Session VII: Challenging Settings for Patients with Lymphoma
Moderators: Jordan Scott Goldstein, MD, Stanford Medicine, Palo Alto, California , Jean Koff, MD, Winship Cancer Institute.
13:30pm
Peripheral T-cell lymphomas and strategies for first-line treatment
Steve Horwitz, MD - Memorial Sloan Kettering Cancer Center, New York
13:50pm
How should we sequence therapy for patients with cutaneous T-cell lymphomas
TBD TBD
14:10pm
What’s new for older patients with Lymphoma?
Elizabeth A. Brem, MD - UC Irvine Health Cancer Center, California
14:30pm
Panel Discussion
14:50pm
Coffee Break
Session VIII: The future of therapies for B-cell lymphomas
Moderators: Joe Schroers-Martin, MD, Stanford University, Dai Chihara, MD, MD Anderson Cancer Centre
15:10pm
Future therapeutic strategies for targeting the microenvironment in lymphomas
Michael R. Green - MD Anderson Cancer Center, Houston, Texas
15:30pm
Building models for aggressive lymphomas,
Jean Koff, MD - Winship Cancer Institute of Emory University, Georgia
Debate: New therapy development - Models vs. Drugs
15:50pm
Point: The best models will improve outcomes for patients with lymphoma
Christopher Flowers, MD - MD Anderson Cancer Center, Houston, Texas
16:10pm
Counterpoint: The best drugs will improve outcomes for patients with lymphoma
Jonathon B. Cohen, MD - Emory Healthcare, Atlanta, Georgia
